- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LAKESHORE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 06.02. | LakeShore Biopharma's $0.90 per share going-private deal at risk | 1 | Investing.com | ||
| 06.02. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.01. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.01. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.11.25 | NSE - LakeShore Biopharma Co., Ltd. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | - | SEC Filings | ||
| 04.11.25 | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.09.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.09.2025 | 1.080 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 30.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.09.2025ISIN NameCA8875221001 TINKA... ► Artikel lesen | |
| 22.09.25 | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.09.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting | 266 | PR Newswire | BEIJING, Sept. 22, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 12.09.25 | LakeShore Biopharma faces Nasdaq delisting after failing to meet bid price rule | 2 | Investing.com | ||
| 12.09.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq | 891 | PR Newswire | BEIJING, Sept. 12, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 10.09.25 | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.09.25 | LakeShore Biopharma appoints advisors to evaluate buyout proposal | 1 | Investing.com | ||
| 28.08.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee | 538 | PR Newswire | BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 18.08.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company | 229 | PR Newswire | BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 31.07.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Fiscal Year 2025 Financial Results | 134 | PR Newswire | Total revenue reached RMB615.0 million, representing 7.2% year-over-year growth
Gross profit rose to RMB507.2 million, up 11.3% year-over-year
Gross margin improved... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 15,120 | 0,00 % | Erasca, Inc.: Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat | ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO... ► Artikel lesen | |
| DYNE THERAPEUTICS | 15,230 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | - Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,545 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| QIAGEN | 39,810 | -2,61 % | Shortseller-Positionen aktuell: freenet, Gerresheimer, Hypoport, Qiagen, Renk, Suss MicroTec, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 86,15 | 0,00 % | Kymera auf TD Cowen Konferenz: Strategische Einblicke in Medikamenten-Pipeline und Partnerschaften | ||
| ARCELLX | 114,26 | 0,00 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 27,410 | 0,00 % | Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF")... ► Artikel lesen | |
| UPSTREAM BIO | 7,800 | 0,00 % | Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting | - Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p in new analysis with adjustment for concomitant rescue therapy use - - Secondary endpoints also provided strong... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,070 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| BIONTECH | 89,05 | -0,17 % | BioNTech Aktie: Die Wende naht! Golden Cross! | © Foto: 2026 BioNTech SE. Alle Recht vorbehalten.Fast wie in der Serie "Game of Thrones", wo der Winter naht, könnte bei BioNTech die Wende nahen. Nach dem Kursrausch in der Corona-Ära folgte der brutale... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,370 | 0,00 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| DISC MEDICINE | 61,04 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026Initial... ► Artikel lesen | |
| NUVALENT | 102,71 | 0,00 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results | Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 72,25 | 0,00 % | RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook | ||
| VERA THERAPEUTICS | 39,650 | 0,00 % | Vera Therapeutics, Inc. - 10-K, Annual Report |
Das Unternehmen LAKESHORE BIOPHARMA CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,665 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAKESHORE BIOPHARMA CO LTD finden Sie auf Wallstreet Online.